Trials / Completed
CompletedNCT01886053
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
A Phase II Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faropenem（high dose group） | dosage form: Injection dosage:2400 mg frequency: Three times a day |
| DRUG | Faropenem（low-dose group) | dosage form: Injection dosage:2400 mg frequency: twice a day |
| DRUG | Ertapenem | dosage form: Injection dosage:1000 mg frequency: once a day |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2013-06-25
- Last updated
- 2013-06-25
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01886053. Inclusion in this directory is not an endorsement.